Needham analyst Joseph Stringer downgraded Inozyme (INZY) to Hold from Buy without a price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme downgraded to Equal Weight from Overweight at Wells Fargo
- Inozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential
- BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
- Inozyme downgraded to Neutral from Outperform at Wedbush
- Inozyme Pharma Merges with BioMarin for $270 Million